Advancements in Multiple Myeloma Treatment

This chapter explores cutting-edge developments in treating multiple myeloma, particularly through tri-specific T cell engagers and the re-approval of belantamab in the UK. It discusses promising trial results, the integration of anti-CD38 therapies, and the significance of minimal residual disease (MRD) monitoring in improving patient outcomes. Ongoing research and future considerations for combination therapies and regulatory approvals are also highlighted.